The alternative text for this image may have been generated using AI. Figure 4: D4A inhibits xenograft steroidogenesis and growth. The alternative text for this image may have been generated using AI.
Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors
A metabolite of an FDA-approved drug for metastatic prostate cancer, abiraterone, has more anti-cancer properties than its precursor, researchers have discovered for the first time. Prostate cancer is ...
Evaluating abiraterone responses in African Americans with metastatic CRPC. This is an ASCO Meeting Abstract from the 2016 Genitourinary Cancers Symposium. This abstract does not include a full text ...
New research shows that abiraterone is converted to a metabolite that has a wider range of inhibitory activity and might be more clinically effective in the treatment of patients with prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results